Tislelizumab – July 2026

  • Solution concentrate for I.V. infusion 100 mg in 10 ml
  • Solution concentrate for I.V. infusion 150 mg in 15 ml

  • Brand names:
    • Tevimbra®
  • Pharmaceutical Company:
    • BEONE MEDICINES AUS PTY LTD
  • Condition/Indication: Gastro-oesophageal cancer
  • Meeting Date:

Last updated
13 November 2026